Illinois Governor Opens 2010 BIO International Convention, Meets Vetter

Illinois Governor Pat Quinn cut the ribbon at the 2010 BIO International Convention and met with industry leaders, including executives from Vetter, a provider of aseptic prefilled drug-delivery systems.

This is the second time in four years that BIO has held its annual convention in Chicago, underscoring the region’s rising influence in the biotech industry.  Germany-based Vetter chose Chicago when it decided to expand its Vetter Development Service. The company’s facility, located in Skokie’s Illinois Science + Technology Park, will support preclinical through phase II projects, and will be operational at the beginning of the fourth quarter 2010.
 
Said Peter Soelkner, Vetter managing director, in a press release: “The decision to base our North American operations in Chicago was a critical element of our strategic growth plan for Vetter. The Midwest location fit like a glove. Centrally located within the United States, it enables us to travel easily to all of our North American customers, and they to us. It is also within a thriving center of biotechnology industry and top-flight academic institutions. That gives us access to colleagues, cutting-edge science and a highly skilled employee pool.”
 

Governor Pat Quinn (fourth from left) greeted Vetter executives (from
left to right) Gunther Strothe, Max Horn, Peter Soelkner, Udo J. Vetter (Chairman), Wolfgang Kerkhoff; and
the Mayor of Skokie, George Van Dusen (second from right).  

 

“Illinois biotechnology is helping to drive advances in medicine and agriculture,” said Governor Quinn. “We’re not surprised that the rest of the world is discovering what we have to offer.” Biotechnology’s share of total venture investment in Illinois in 2009 reached 21%.
 
On May 4, as part of BIO’s Contract Services Summit, Dr. Claudia Roth, site manager of Vetter´s new Chicago facility, presented “Design and Implementation of a Fast and Flexible Clinical-Trial-Material Manufacturing Site in the United States.” She discussed approaches to clinical manufacturing developed by Vetter, from the focus on disposable technology, to minimizing API losses via automated sample filling, to rapid implementation of manufacturing processes.  

No votes yet